Overview
U.S. biopharmaceutical firm's Q1 net loss narrowed yr/yr as operating expenses declined
Company entered asset purchase agreement with Jazz Pharmaceuticals for IFNα program
All obligations under loan agreement with K2 HealthVentures repaid after quarter end
Outlook
Company plans to update cash runway guidance in the near future
Result Drivers
LOWER R&D SPENDING - Q1 research and development expenses declined yr/yr, contributing to narrower net loss
Company press release: ID:nGNX4PxJl1
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$13.53 mln
Q1 Basic EPS
-$0.28
Q1 Operating Expenses
$13.27 mln
Q1 Operating Income
-$13.27 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Werewolf Therapeutics Inc is $7.00, about 976.6% above its May 6 closing price of $0.65
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
